EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Bispecific Antibodies and T‐Cell Engagers in Multiple Myeloma

Mahin Bhatt iD, S Vincent Rajkumar iD, Shaji Kumar iD

European Journal of Haematology · 2026-12 · 117 (6) · 1461-1474

DOI: 10.1111/ejh.70301 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 25.08.2026. Verfasst von Mahin Bhatt und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Multiple Myeloma, T-Lymphocytes, Antineoplastic Agents, Immunological. Die Arbeit nennt 81 Literaturangaben. Gefördert von: National Institutes of Health, USA, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bispecific antibodies have reshaped the therapeutic landscape for relapsed/refractory multiple myeloma (RRMM), complementing proteasome inhibitors, IMiDs, and anti‐CD38 antibodies and competing with BCMA‐directed CAR‐T cells. In this review, we discuss the structure, mechanisms of action, and clinical data for currently approved and emerging T‐cell redirecting antibodies and discuss practical questions around sequencing with CAR‐T therapy, toxicity mitigation, and resistance. Bispecific T‐cell engagers have shown high response rates in early relapse, as well as multidrug‐refractory disease and post‐CAR‐T relapse, but are limited by continuous dosing, infections, hypogammaglobulinemia, cytopenias, cytokine release syndrome (CRS), and neurologic toxicity. We review emerging concepts in resistance like T‐cell exhaustion, antigen loss, soluble BCMA, and extramedullary disease and discuss strategies to enhance efficacy, including combinations with anti‐CD38 antibodies and IMiDs. Bispecific antibodies have become indispensable in relapsed myeloma, and for patients who are ineligible for or relapse after CAR‐T therapy. With multiple clinical trials and new molecules in development, rational sequencing and combination approaches will determine how far their promise translates into durable disease control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificMultiple MyelomaT-LymphocytesAntineoplastic Agents, ImmunologicalHumansImmunotherapy, AdoptiveB-Cell Maturation AntigenADP-ribosyl Cyclase 1Treatment Outcome

Stichwörter der Autor:innen

B‐cell maturation antigenT‐cell engagerbispecific antibodieschimeric antigen receptor T‐cellsmultiple myeloma

Substanzen

Antibodies, BispecificAntineoplastic Agents, ImmunologicalB-Cell Maturation AntigenADP-ribosyl Cyclase 1

Autor:innen und Institutionen

  • Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Mahin Bhatt, S Vincent Rajkumar, Shaji Kumar

Förderung

  • National Institutes of Health, USA
  • National Institutes of Health

Zitieren

APA

Bhatt, M., Rajkumar, S. V., & Kumar, S. (2026). Bispecific Antibodies and T‐Cell Engagers in Multiple Myeloma. European Journal of Haematology, 117(6), 1461-1474. https://doi.org/10.1111/ejh.70301

Vancouver

Bhatt M, Rajkumar SV, Kumar S. Bispecific Antibodies and T‐Cell Engagers in Multiple Myeloma. European Journal of Haematology. 2026;117(6):1461-1474. doi:10.1111/ejh.70301

BibTeX
@article{Bhatt2026,
  author = {Bhatt, Mahin and Rajkumar, S Vincent and Kumar, Shaji},
  title = {Bispecific Antibodies and T‐Cell Engagers in Multiple Myeloma},
  journal = {European Journal of Haematology},
  year = {2026},
  volume = {117},
  number = {6},
  pages = {1461--1474},
  doi = {10.1111/ejh.70301}
}
Kostenlos starten →